New hope for blood cancer patients: tazemetostat studied in Real-World setting
NCT ID NCT07282548
First seen Jan 09, 2026 · Last updated May 21, 2026 · Updated 17 times
Summary
This study looks at how well the drug tazemetostat works in adults with follicular lymphoma, a slow-growing blood cancer, that has returned or not responded after at least two prior treatments. Participants take tazemetostat as prescribed by their doctor in routine care. The study tracks tumor shrinkage, how long benefits last, and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.